{ "schema_version": 1, "kind": "condition", "id": "premature-ovarian-insufficiency", "name": "Premature ovarian insufficiency", "category": "chronic", "sources": "ICPC-3 (WONCA International Classification of Primary Care, 3rd edition) class TD99.08 - condition scope only, no dose · No dose - referral pathway, no medicine given in primary care · Primary Ovarian Insufficiency - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK589674/ · Premature ovarian insufficiency - disease-level clinical article (premature-ovarian-insufficiency-full.txt), which states the transdermal/transvaginal dose and the duration, with the oral figure and the contraindication block from Egyptian National Drug Formulary - Endocrine System 2024 (estradiol monograph) · Egyptian National Drug Formulary - Endocrine System 2024 (progesterone monograph, Dosage regimen, Oral: Adjunctive use with Estrogen, as hormone replacement therapy), with the indication in premenopausal women from Premature ovarian insufficiency - disease-level clinical article (premature-ovarian-insufficiency-full.txt) · Premature ovarian insufficiency - disease-level clinical article (premature-ovarian-insufficiency-full.txt)", "review_status": "reviewed", "verified_against": "No dose - referral pathway, no medicine given in primary care · Premature ovarian insufficiency - disease-level clinical article (premature-ovarian-insufficiency-clinical.txt) · Premature ovarian insufficiency - disease-level clinical article (premature-ovarian-insufficiency-full.txt), which states the transdermal/transvaginal dose and the duration, with the oral figure and the contraindication block from Egyptian National Drug Formulary - Endocrine System 2024 (estradiol monograph) · Egyptian National Drug Formulary - Endocrine System 2024 (progesterone monograph, Dosage regimen, Oral: Adjunctive use with Estrogen, as hormone replacement therapy), with the indication in premenopausal women from Premature ovarian insufficiency - disease-level clinical article (premature-ovarian-insufficiency-full.txt) · Premature ovarian insufficiency - disease-level clinical article (premature-ovarian-insufficiency-full.txt)", "verified_date": "2026-08", "treatments": [ { "id": 1471, "generic": "No drug therapy in primary care (Referral & Advice)", "line": 1, "is_adjunct": false, "form": null, "strength_mg": null, "adult_dose": "Premature ovarian insufficiency, occurring well before the usual age of menopause, affects fertility and long-term bone and cardiovascular health; the GP recognises the presentation and refers to gynaecology or endocrinology, with hormone therapy often needed.", "adult_duration": "Refer, with advice", "dose_source": "No dose - referral pathway, no medicine given in primary care", "rationale": "Premature ovarian insufficiency, occurring well before the usual age of menopause, affects fertility and long-term bone and cardiovascular health; the GP recognises the presentation and refers to gynaecology or endocrinology, with hormone therapy often needed.", "cautions": [ "Consider an underlying autoimmune or genetic cause; there is a long-term risk of osteoporosis and cardiovascular disease if untreated.", "Hormone replacement is started and monitored by gynaecology or endocrinology. The oestrogen and progestogen rows on this card exist so that the regimen, its duration and its requirements are visible - and so that a woman already on it is not left without it - not so that it is initiated here.", "RED FLAG - Close follow-up is required to ensure adequate hormone replacement and to monitor for treatment complications." ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": "Children follow the same pathway: recognise and refer. No primary-care medicine is implied.", "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": null, "peds_doses": null, "brands": [], "condition_id": "premature-ovarian-insufficiency" }, { "id": 1472, "generic": "Estradiol", "line": 1, "is_adjunct": false, "form": "topical", "strength_mg": null, "adult_dose": "0.100 mg (100 micrograms) of estradiol daily by transdermal patch or vaginal ring - the article's regimen, and the routes it prefers. The Egyptian formulary's oral figure, for comparison, is estradiol valerate 1 mg daily, increased to 2 mg if needed.", "adult_duration": "Until the average age of natural menopause - the article's figure is 50.5 years", "dose_source": "Premature ovarian insufficiency - disease-level clinical article (premature-ovarian-insufficiency-full.txt), which states the transdermal/transvaginal dose and the duration, with the oral figure and the contraindication block from Egyptian National Drug Formulary - Endocrine System 2024 (estradiol monograph)", "rationale": "The card carried no oestrogen at all, which is why the earlier attempt to add the progestogen the article calls imperative could not stand - it would have been an adjunct to nothing. The article states the indication, the dose, the route and the duration in one place: estradiol (17B-E2) replacement is the mainstay for POI, given transvaginally or by transdermal patch, both of which lower the overall venous thromboembolism risk against oral replacement; a vaginal ring, or a patch, puts out 0.100 milligrams of estradiol a day. The international figure leads and the Egyptian formulary's oral 1-2 mg is noted beside it - and here the difference is route, not strength: the article prefers the non-oral routes for a stated reason (VTE). Egypt registers the matching patch (FEM 7 100 mcg, 50 EGP) as well as 50 and 75 mcg strengths.", "cautions": [ "GIVEN WITH a progestogen whenever the uterus is intact. The formulary puts it on the oestradiol monograph itself: where the uterus is still there, a progestogen goes alongside the oestradiol, for 12 to 14 days at the least, in every 28-day cycle, begun on the first day of the bleed. Oestrogen on its own is appropriate only for a woman who has had a hysterectomy.", "CONTRAINDICATED - the formulary bars it in: endometrial hyperplasia that has not been treated; breast cancer, known or suspected; an oestrogen-dependent tumour; genital bleeding that has not been explained; deep vein thrombosis or pulmonary embolism, whether active now or in the past; and recent arterial thromboembolic disease. On the liver: it is contraindicated where hepatic function is actively disturbed.", "Why replace at all - the article's case for oestrogen replacement in POI: it takes away the vasomotor symptoms, keeps bone density up and fracture risk down, lowers illness and death from cardiovascular and autoimmune causes, guards cognition, and leaves the woman better in herself overall.", "The target - treatment aims to hold the oestradiol at 100 pg/mL day by day, the level a premenopausal woman with working ovaries runs at. This is replacement to a normal premenopausal level, not menopausal symptom control, and the dose is higher than a postmenopausal HRT dose for that reason.", "A combined oral contraceptive is NOT an equivalent substitute. It carries more venous thromboembolism than replacement does, and it fails to deliver the daily physiological level the woman needs.", "Started and monitored by gynaecology or endocrinology. This row exists so the regimen and its requirements are visible in primary care, and so that a woman already on it is not left without it.", "The Egyptian product this row means is the FEM 7 transdermal patch, registered at 50, 75 and 100 micrograms. The route is recorded as topical because the register files patches without a route and that is what finds them; it is a skin patch, not a cream. Two other products file under the same ingredient name and are deliberately excluded from this row - ETHINYL OESTRADIOL tablets (a different molecule, the contraceptive oestrogen) and FOLONE oily ampoules (an intramuscular depot)." ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": "Not a paediatric prescription. Adolescents with primary ovarian insufficiency (Turner syndrome, for example) need induction of puberty on a paediatric-endocrine schedule, which no document held here states.", "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": null, "peds_doses": null, "brands": [ { "trade_name": "FEM 7 - 50 MCG 4 TRANSDERMAL PATCHES", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "MERCK KGAA F.R.GERMANY > MERCK KGAA F.R-EGYPT", "price_egp": 30.0, "pack_count": null, "unit_price": null, "strength_mg": 0.05, "exact_strength": true, "exact_form": false, "discontinued": false, "also_contains": null }, { "trade_name": "FEM 7 - 75 MCG 4 TRANSDERMAL PATCHES", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "MERCK KGAA F.R.GERMANY > MERCK KGAA F.R-EGYPT", "price_egp": 40.0, "pack_count": null, "unit_price": null, "strength_mg": 0.075, "exact_strength": true, "exact_form": false, "discontinued": false, "also_contains": null }, { "trade_name": "FEM 7 - 100 MCG 4 TRANSDERMAL PATCHES", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "MERCK KGAA F.R.GERMANY > MERCK KGAA F.R-EGYPT", "price_egp": 50.0, "pack_count": null, "unit_price": null, "strength_mg": 0.1, "exact_strength": true, "exact_form": false, "discontinued": false, "also_contains": null } ], "condition_id": "premature-ovarian-insufficiency" }, { "id": 1473, "generic": "Progesterone", "line": 1, "is_adjunct": false, "form": "oral.solid", "strength_mg": 200.0, "adult_dose": "200 mg at bedtime for 12 days, from day 15 to day 26 of the cycle; or 100 mg at bedtime from day 1 to day 25 of each cycle, which causes less withdrawal bleeding", "adult_duration": "For as long as the oestrogen is taken, in every woman with a uterus", "dose_source": "Egyptian National Drug Formulary - Endocrine System 2024 (progesterone monograph, Dosage regimen, Oral: Adjunctive use with Estrogen, as hormone replacement therapy), with the indication in premenopausal women from Premature ovarian insufficiency - disease-level clinical article (premature-ovarian-insufficiency-full.txt)", "rationale": "An earlier review refused this on a population mismatch: the article calls it imperative in premenopausal women and the formulary's oral indication names post-menopausal women. Under the two-claims ruling, monograph indication silence or narrowness is not prohibition - only an outright contraindication blocks a row, and there is none here. The article supplies the indication: in premenopausal women, progesterone supplementation is imperative, to prevent endometrial hyperplasia and the progression to endometrial carcinoma that can follow it. The formulary supplies the regimen for exactly this use - adjunctive to an oestrogen as hormone replacement therapy. Micronised oral progesterone is widely registered in Egypt (22 products).", "cautions": [ "NOT A STANDALONE TREATMENT. It is here to protect the endometrium from the oestrogen it is paired with; the formulary indication for the oral form is as an adjunct, given with an oestrogen as hormone replacement to a postmenopausal woman whose uterus is intact. The link to premenopausal women with POI comes from the disease article.", "Not needed after hysterectomy - where the uterus is gone, the article accepts oestrogen alone as the appropriate treatment for POI.", "The article does not restrict the route: progesterone may be given by mouth or through the skin. The dose printed here is the oral one, because that is the regimen the formulary states.", "CONTRAINDICATED - the formulary bars it in: cancer of the breast, known or suspected or in the history, and cancer of the genital tract; arterial thromboembolic disease current or past, stroke and myocardial infarction among them, and thrombophlebitis; vaginal bleeding that has not been explained; deep vein thrombosis or pulmonary embolism, active or past; a missed abortion, or an ectopic pregnancy; cerebral haemorrhage; and porphyria. Systemically it is contraindicated where the liver is impaired.", "Withdrawal bleeding is expected on the day-15-to-26 schedule, and the formulary says as much: a bleed may follow in the week afterwards. The continuous 100 mg schedule bleeds less, which matters to a woman under 40 who is not expecting her periods to start up again.", "Started and monitored by gynaecology or endocrinology alongside the oestrogen." ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": "Not a paediatric prescription; adolescent induction regimens are a paediatric-endocrine matter and no document held here states one.", "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": null, "peds_doses": null, "brands": [ { "trade_name": "UTROCARE 200 MG 30 S.G. CAPS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "SAFE PHARMA > OCTOBER PHARMA", "price_egp": 204.0, "pack_count": null, "unit_price": null, "strength_mg": 200.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "PROGEST 200MG 30 ORAL/VAGINAL CAPS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "PHARCO", "price_egp": 246.0, "pack_count": null, "unit_price": null, "strength_mg": 200.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "HYSTROGEST 200 MG 30 S.G.CAPS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "SAFE PHARMA > GLOBE INTERNATIONAL PHARMACEUTICALS", "price_egp": 264.0, "pack_count": null, "unit_price": null, "strength_mg": 200.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null } ], "condition_id": "premature-ovarian-insufficiency" } ] }